Cozad Asset Management Inc. Sells 830 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Cozad Asset Management Inc. reduced its holdings in Thermo Fisher Scientific Inc. by 8% in Q1, now owning 9,575 shares valued at approximately $4.77 million.
• Thermo Fisher's quarterly earnings beat estimates, reporting $5.36 EPS and revenue of $10.86 billion, which represents a year-over-year growth of 2.9%.
• The company recently announced a quarterly dividend of $0.43 per share, with a yield of 0.35% based on an annualized payout of $1.72.

Cozad Asset Management Inc. lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,575 shares of the medical research company's stock after selling 830 shares during the period. Cozad Asset Management Inc.'s holdings in Thermo Fisher Scientific were worth $4,765,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Bernard Wealth Management Corp. bought a new position in Thermo Fisher Scientific during the 4th quarter valued at about $25,000. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $30,000. IMA Advisory Services Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at about $35,000. Navigoe LLC purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at about $37,000. Institutional investors own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.33% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. HSBC reissued a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a report on Thursday, July 24th. Argus reduced their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Raymond James Financial reissued an "outperform" rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Royal Bank Of Canada reduced their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Six research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $593.00.

Thermo Fisher Scientific Trading Down 1.4%

TMO stock traded down $6.33 during midday trading on Friday, reaching $461.35. The company's stock had a trading volume of 2,002,967 shares, compared to its average volume of 2,525,832. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock has a fifty day simple moving average of $419.50 and a two-hundred day simple moving average of $468.31. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The firm has a market capitalization of $174.16 billion, a price-to-earnings ratio of 26.70, a PEG ratio of 2.55 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The business's revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the firm posted $5.37 earnings per share. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.